uniQure
QURE
#5350
Rank
S$2.07 B
Marketcap
S$29.56
Share price
1.34%
Change (1 day)
-13.20%
Change (1 year)

P/E ratio for uniQure (QURE)

P/E ratio as of November 2026 (TTM): -5.24

According to uniQure's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.2448. At the end of 2022 the company had a P/E ratio of -8.37.

P/E ratio history for uniQure from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-8.37-388.39%
20212.90-122.56%
2020-12.9-44.02%
2019-23.086.49%
2018-12.384.84%
2017-6.66248.63%
2016-1.91-58.04%
2015-4.55-7.31%
2014-4.91

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Amgen
AMGN
26.8-610.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
24.4-564.31%๐Ÿ‡ซ๐Ÿ‡ท France
Sangamo Therapeutics
SGMO
-0.1947-96.29%๐Ÿ‡บ๐Ÿ‡ธ USA
bluebird bio
BLUE
-0.2003-96.18%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
-635 12,003.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
-17.4 232.16%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.